Exosome Diagnostics
Kurt Franzen is a seasoned professional with extensive experience in research and development within the biotechnology and pharmaceutical industries. Currently serving as Team Manager in Research and Development at Exosome Diagnostics since February 2019, Kurt previously held various positions including Scientist and Associate Scientist at Histogenics Corporation, where analytical development for cell/tissue therapy projects was a key focus. Additional roles include Research Scientist at Aushon BioSystems, Technician in Process Development at the University of North Carolina at Chapel Hill, and Senior Associate Research Scientist at Grifols. Kurt's career began with substantial contributions in assay development and validation at organizations such as CancerGuide Diagnostics, ParagonDx LLC, and Praecis Pharmaceuticals, alongside a foundational background as Senior Research Associate at Boston University School of Medicine. Kurt holds a Bachelor of Science in Biology and Chemistry from the University of North Carolina at Greensboro.
This person is not in any offices
Exosome Diagnostics
Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technologymakes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.